▶ 調査レポート

色素沈着過剰症治療の世界市場分析・規模・シェア・成長・動向・予測:治療法別(局所治療薬、レーザー治療、ケミカルピーリング、マイクロダーマブレーション)、適応症別(肝斑、炎症後色素沈着過剰症、日光性黒子)、最終用途別(病院、美容クリニック・皮膚センター)

• 英文タイトル:Hyperpigmentation Disorders Treatment Market (Treatment Type - Topical Drugs, Laser Therapy, Chemical Peels, Phototherapy, Microdermabrasion; Disease Indication - Melasma, Post-inflammatory Hyperpigmentation, Solar Lentigines; End use - Hospitals, Aesthetic Clinics & Dermatology Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Transparency Market Researchが調査・発行した産業分析レポートです。色素沈着過剰症治療の世界市場分析・規模・シェア・成長・動向・予測:治療法別(局所治療薬、レーザー治療、ケミカルピーリング、マイクロダーマブレーション)、適応症別(肝斑、炎症後色素沈着過剰症、日光性黒子)、最終用途別(病院、美容クリニック・皮膚センター) / Hyperpigmentation Disorders Treatment Market (Treatment Type - Topical Drugs, Laser Therapy, Chemical Peels, Phototherapy, Microdermabrasion; Disease Indication - Melasma, Post-inflammatory Hyperpigmentation, Solar Lentigines; End use - Hospitals, Aesthetic Clinics & Dermatology Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026 / TPM-BG042資料のイメージです。• レポートコード:TPM-BG042
• 出版社/出版日:Transparency Market Research / 2018年7月
• レポート形態:英文、PDF、201ページ
• 納品方法:Eメール
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥857,660 (USD5,795)▷ お問い合わせ
  Multi User¥1,301,660 (USD8,795)▷ お問い合わせ
  Global Site License¥1,745,660 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本資料は、色素沈着過剰症治療の世界市場について調べ、色素沈着過剰症治療の世界規模、市場動向、市場環境、治療法別(局所治療薬、レーザー治療、ケミカルピーリング、マイクロダーマブレーション)分析、適応症別(肝斑、炎症後色素沈着過剰症、日光性黒子)分析、最終用途別(病院、美容クリニック・皮膚センター)分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、関連企業情報などをまとめた調査レポートです。
・序文・調査範囲・調査手法
・エグゼクティブサマリー
・色素沈着過剰症治療の世界市場動向
・色素沈着過剰症治療の世界市場環境
・色素沈着過剰症治療の世界市場規模
・色素沈着過剰症治療の世界市場規模:治療法別(局所治療薬、レーザー治療、ケミカルピーリング、マイクロダーマブレーション)
・色素沈着過剰症治療の世界市場規模:適応症別(肝斑、炎症後色素沈着過剰症、日光性黒子)
・色素沈着過剰症治療の世界市場規模:最終用途別(病院、美容クリニック・皮膚センター)
・色素沈着過剰症治療の世界市場:地域別市場規模・分析
・色素沈着過剰症治療の北米市場規模・予測
・色素沈着過剰症治療のアメリカ市場規模・予測
・色素沈着過剰症治療の中南米市場規模・予測
・色素沈着過剰症治療のヨーロッパ市場規模・予測
・色素沈着過剰症治療のアジア市場規模・予測
・色素沈着過剰症治療の日本市場規模・予測
・色素沈着過剰症治療の中国市場規模・予測
・色素沈着過剰症治療のインド市場規模・予測
・色素沈着過剰症治療の中東市場規模・予測
・色素沈着過剰症治療のアフリカ市場規模・予測
・競争状況・関連企業情報

Global Hyperpigmentation Disorders Treatment Market: Overview

This report analyzes the global hyperpigmentation disorders treatment market in terms of its current and future scenario. Rise in investment in R&D of novel advanced technologies, decrease in social taboos regarding pigmentation, increase in prevalence of hyperpigmentation-related disorders, and rise in awareness about skin rejuvenation and treatment options are likely to drive the growth of the global market during the forecast period. Anti-pigmentation therapies can be classified as topical drugs, microdermabrasion, chemical peels, and laser therapy. These therapies are available in hospitals and aesthetic clinics & dermatology centers.

This report on the global hyperpigmentation disorders treatment market comprises an elaborate executive summary, including a market snapshot that provides information about various segments of the market. The report also provides information and data analysis of the global market with respect to its segments based on product type, application, and geography. A detailed qualitative analysis of drivers, restraints, and opportunities of the market has been provided in the market overview section. In addition, the section comprises competitive matrix and company profiles with business overview to project the competitive landscape of the market. It also provides market attractiveness analysis in terms of geography, and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario prevailing in the global hyperpigmentation disorders treatment market.

Global Hyperpigmentation Disorders Treatment Market: Key Segments

The global hyperpigmentation disorders treatment market has been segmented into topical drugs, laser therapy, chemical peels, microdermabrasion, phototherapy, and others, based on treatment type. By disease indication, the market has been classified into melasma, post-inflammatory hyperpigmentation, solar lentigines, and others. In terms of end-user, the market has been segmented into hospitals, aesthetic clinics & dermatology centers, and others. The global hyperpigmentation disorders treatment market has been analyzed based on increasing prevalence of hyperpigmentation disorders, technology trend, expenditure on emerging technologies, and presence of key players in the region. Market size and forecast for each of these segments have been provided for the period of 2016 to 2026, along with their respective CAGR for the forecast period, i.e. from 2018 to 2026, considering 2017 as the base year.

Global Hyperpigmentation Disorders Treatment Market: Regional Outlook

Geographically, the global hyperpigmentation disorders treatment market has been categorized into five major regions and key countries in these regions: North America (the U.S., Canada), Europe (the U.K., Germany, France, Italy, Spain, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC, South Africa, Israel, and Rest of Middle East & Africa). Market size and forecast for each of these regions and their key countries have been provided for the period of 2016 to 2026, along with their respective CAGR for the forecast period, viz. 2018-2026, considering 2017 as the base year. This report also covers the competitive scenario of the market in these regions.

Companies Mentioned in Report

The report profiles the major players operating in the global hyperpigmentation disorders treatment market in terms of attributes, such as, company overview, financial overview, product portfolio, business strategies, and recent developments. Major companies profiled in this report are Bayer AG, ALLERGAN, Galderma S.A., SkinCeuticals, Pierre Fabre, EpiPharm AG, RXi Pharmaceuticals Corporation, Obagi Cosmeceuticals LLC, and Vivier Pharma.

The global hyperpigmentation disorders treatment market has been segmented as follows:

Hyperpigmentation Disorders Treatment Market, by Treatment Type

Topical Drugs
Laser Therapy
Chemical Peels
Microdermabrasion
Phototherapy
Others
Hyperpigmentation Disorders Treatment Market, by Disease Indication

Melasma
Post-inflammatory Hyperpigmentation
Solar Lentigines
Others
Hyperpigmentation Disorders Treatment Market, by End-user

Hospitals
Aesthetic Clinics & Dermatology Centers
Others
Hyperpigmentation Disorders Treatment Market, by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
Australia & New Zealand
India
Rest of Asia-pacific
Latin America
Brazil
Mexico
Rest of Latin America
Middle East & Africa
GCC
South Africa
Israel
Rest of Middle East & Africa

レポート目次

Section 01: Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights

Section 02: Assumptions and Research Methodology

2.1 Assumptions
2.2 Research Methodology

Section 03: Executive Summary
3.1 Global Hyperpigmentation Disorders Treatment Market Size (US$ Mn) and Distribution by Geography, 2017 and 2026
3.2 Global Hyperpigmentation Disorders Treatment Market Snapshot, 2017
3.3 Global Hyperpigmentation Disorders Treatment Market: Opportunity Map

Section 04: Market Overview
4.1 Overview
4.2 Global Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, 2016–2026
4.3 Global Hyperpigmentation Disorders Treatment Market Outlook
4.4 Global Hyperpigmentation Disorders Treatment Market: Porter’s Five Forces Analysis
4.5 Hyperpigmentation Disorders Treatment Market: Pipeline Analysis
4.6 Key Partnership & Acquisitions
4.7 Policies and Regulations: By Region
4.8 Disease Prevalence and Incidence Rate Globally
4.9 Global Hyperpigmentation Disorders Treatment Market: Pricing Assessment

Section 05: Market Dynamics
5.1 Drivers
5.2 Restraints
5.3 Opportunity Analysis
5.4 Opportunities
5.5 Trends

Section 06: Global Hyperpigmentation Disorders Treatment Market Analysis, by Treatment Type
6.1 Introduction
6.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by Treatment Type
6.3 Hyperpigmentation Disorders Treatment Market Analysis, by Treatment Type
6.3.1 Topical Drugs
6.3.2 Laser Therapy
6.3.3 Chemical Peels
6.3.4 Microdermabrasion
6.3.5 Phototherapy
6.3.6 Others
6.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by Treatment Type

Section 07: Global Hyperpigmentation Disorders Treatment Market Analysis, by Disease Indication
7.1 Introduction
7.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by Disease Indication
7.3 Hyperpigmentation Disorders Treatment Market Analysis, by Disease Indication
7.3.1 Melasma
7.3.2 Post-inflammatory Hyperpigmentation
7.3.3 Solar Lentigines
7.3.4 Others
7.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by Disease Indication

Section 08: Global Hyperpigmentation Disorders Treatment Market Analysis, by End-user
8.1 Introduction
8.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by End-user
8.3 Hyperpigmentation Disorders Treatment Market Analysis, by End-user
8.3.1 Hospitals
8.3.2 Aesthetic Clinics & Dermatology Centers
8.3.3 Others
8.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by End-user

Section 09: Global Hyperpigmentation Disorders Treatment Market Analysis, by Region
9.1 Global Hyperpigmentation Disorders Treatment Market Snapshot, by Country
9.2 Global Hyperpigmentation Disorders Treatment Market Value Share Analysis, by Region
9.3 Hyperpigmentation Disorders Treatment Market Forecast, by Region
9.3.1 North America
9.3.2 Europe
9.3.3 Asia Pacific
9.3.4 Latin America
9.3.5 Middle East & Africa
9.4 Hyperpigmentation Disorders Treatment Market Attractiveness Analysis, by Region

Section 10: North America Hyperpigmentation Disorders Treatment Market Analysis
10.1 Key Findings
10.2 North America Hyperpigmentation Disorders Treatment Market Overview
10.3 North America Market Value Share Analysis, by Treatment Type
10.4 North America Market Forecast, by Treatment Type
10.4.1 Topical Drugs
10.4.2 Laser Therapy
10.4.3 Chemical Peels
10.4.4 Microdermabrasion
10.4.5 Phototherapy
10.4.6 Others
10.5 North America Market Value Share Analysis, by Disease Indication
10.6 North America Market Forecast, by Disease Indication
10.6.1 Melasma
10.6.2 Post-inflammatory Hyperpigmentation
10.6.3 Solar Lentigines
10.6.4 Others
10.7 North America Market Value Share Analysis, by End-user
10.8 North America Market Forecast, by End-user
10.8.1 Hospitals
10.8.2 Aesthetic Clinics & Dermatology Centers
10.8.3 Others
10.9 Market Analysis, by Country
10.10 Market Value Share Analysis, by Country
10.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
10.11.1 U.S.
10.11.2 Canada
10.12 Market Attractiveness Analysis
10.12.1 By Treatment Type
10.12.2 By Disease Indication
10.12.3 By End-user
10.12.4 By Country

Section 11: Europe Hyperpigmentation Disorders Treatment Market Analysis
11.1 Key Findings
11.2 Europe Hyperpigmentation Disorders Treatment Market Overview
11.3 Europe Market Value Share Analysis, by Treatment Type
11.4 Europe Market Forecast, by Treatment Type
11.4.1 Topical Drugs
11.4.2 Laser Therapy
11.4.3 Chemical Peels
11.4.4 Microdermabrasion
11.4.5 Phototherapy
11.4.6 Others
11.5 Europe Market Value Share Analysis, by Disease Indication
11.6 Europe Market Forecast, by Disease Indication
11.6.1 Melasma
11.6.2 Post-inflammatory Hyperpigmentation
11.6.3 Solar Lentigines
11.6.4 Others
11.7 Europe Market Value Share Analysis, by End-user
11.8 Europe Market Forecast, by End-user
11.8.1 Hospitals
11.8.2 Aesthetic Clinics & Dermatology Centers
11.8.3 Others
11.9 Market Analysis, by Country
11.10 Market Value Share Analysis, by Country
11.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
11.11.1 Germany
11.11.2 France
11.11.3 U.K.
11.11.4 Italy
11.11.5 Spain
11.11.6 Rest of Europe
11.12 Market Attractiveness Analysis
11.12.1 By Treatment Type
11.12.2 By Disease Indication
11.12.3 By End-user
11.12.4 By Country

Section 12: Asia Pacific Hyperpigmentation Disorders Treatment Market Analysis
12.1 Key Findings
12.2 Asia Pacific Hyperpigmentation Disorders Treatment Market Overview
12.3 Asia Pacific Market Value Share Analysis, by Treatment Type
12.4 Asia Pacific Market Forecast, by Treatment Type
12.4.1 Topical Drugs
12.4.2 Laser Therapy
12.4.3 Chemical Peels
12.4.4 Microdermabrasion
12.4.5 Phototherapy
12.4.6 Others
12.5 Asia Pacific Market Value Share Analysis, by Disease Indication
12.6 Asia Pacific Market Forecast, by Disease Indication
12.6.1 Melasma
12.6.2 Post-inflammatory Hyperpigmentation
12.6.3 Solar Lentigines
12.6.4 Others
12.7 Asia Pacific Market Value Share Analysis, by End-user
12.8 Asia Pacific Market Forecast, by End-user
12.8.1 Hospitals
12.8.2 Aesthetic Clinics & Dermatology Centers
12.8.3 Others
12.9 Market Analysis, by Country
12.10 Market Value Share Analysis, by Country
12.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
12.11.1 China
12.11.2 Japan
12.11.3 India
12.11.4 Australia & New Zealand
12.11.5 Rest of Asia Pacific
12.12 Market Attractiveness Analysis
12.12.1 By Treatment Type
12.12.2 By Disease Indication
12.12.3 By End-user
12.12.4 By Country

Section 13: Latin America Hyperpigmentation Disorders Treatment Market Analysis
13.1 Key Findings
13.2 Latin America Hyperpigmentation Disorders Treatment Market Overview
13.3 Latin America Market Value Share Analysis, by Treatment Type
13.4 Latin America Market Forecast, by Treatment Type
13.4.1 Topical Drugs
13.4.2 Laser Therapy
13.4.3 Chemical Peels
13.4.4 Microdermabrasion
13.4.5 Phototherapy
13.4.6 Others
13.5 Latin America Market Value Share Analysis, by Disease Indication
13.6 Latin America Market Forecast, by Disease Indication
13.6.1 Melasma
13.6.2 Post-inflammatory Hyperpigmentation
13.6.3 Solar Lentigines
13.6.4 Others
13.7 Latin America Market Value Share Analysis, by End-user
13.8 Latin America Market Forecast, by End-user
13.8.1 Hospitals
13.8.2 Aesthetic Clinics & Dermatology Centers
13.8.3 Others
13.9 Market Analysis, by Country
13.10 Market Value Share Analysis, by Country
13.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
13.11.1 Brazil
13.11.2 Mexico
13.11.3 Rest of Latin America
13.12 Market Attractiveness Analysis
13.12.1 By Treatment Type
13.12.2 By Disease Indication
13.12.3 By End-user
13.12.4 By Country

Section 14: Middle East & Africa Hyperpigmentation Disorders Treatment Market Analysis
14.1 Key Findings
14.2 Middle East & Africa Hyperpigmentation Disorders Treatment Market Overview
14.3 Middle East & Africa Market Value Share Analysis, by Treatment Type
14.4 Middle East & Africa Market Forecast, by Treatment Type
14.4.1 Topical Drugs
14.4.2 Laser Therapy
14.4.3 Chemical Peels
14.4.4 Microdermabrasion
14.4.5 Phototherapy
14.4.6 Others
14.5 Middle East & Africa Market Value Share Analysis, by Disease Indication
14.6 Middle East & Africa Market Forecast, by Disease Indication
14.6.1 Melasma
14.6.2 Post-inflammatory Hyperpigmentation
14.6.3 Solar Lentigines
14.6.4 Others
14.7 Middle East & Africa Market Value Share Analysis, by End-user
14.8 Middle East & Africa Market Forecast, by End-user
14.8.1 Hospitals
14.8.2 Aesthetic Clinics & Dermatology Centers
14.8.3 Others
14.9 Market Analysis, by Country
14.10 Market Value Share Analysis, by Country
14.11 Market Size (US$ Mn) Forecast, by Country, 2018–2026
14.11.1 GCC Countries
14.11.2 South Africa
14.11.3 Rest of Middle East & Africa
14.12 Market Attractiveness Analysis
14.12.1 By Treatment Type
14.12.2 By Disease Indication
14.12.3 By End-user
14.12.4 By Country

Section 15: Competition Landscape
15.1 Competition Matrix
15.2 Hyperpigmentation Disorders Treatment Market Share Analysis, by Company (2017)
15.3 Company Profiles
15.3.1 Bayer AG
15.3.1.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2 Product Portfolio
15.3.1.3 SWOT Analysis
15.3.1.4 Strategic Overview
15.3.1.5 Financial Overview
15.3.2 ALLERGAN
15.3.2.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2 Product Portfolio
15.3.2.3 SWOT Analysis
15.3.2.4 Strategic Overview
15.3.2.5 Financial Overview
15.3.3 Galderma S.A. (Nestle Skin Health S.A)
15.3.3.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2 Product Portfolio
15.3.3.3 SWOT Analysis
15.3.3.4 Strategic Overview
15.3.4 SkinCeuticals
15.3.4.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.4.4 Strategic Overview
15.3.5 Pierre Fabre
15.3.5.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2 Product Portfolio
15.3.5.3 SWOT Analysis
15.3.5.4 Strategic Overview
15.3.5.5 Financial Overview
15.3.6 EpiPharm AG
15.3.6.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2 Product Portfolio
15.3.6.3 SWOT Analysis
15.3.6.4 Strategic Overview
15.3.7 RXi Pharmaceuticals Corporation
15.3.7.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2 Product Portfolio
15.3.7.3 SWOT Analysis
15.3.7.4 Strategic Overview
15.3.7.5 Financial Overview
15.3.8 Obagi Cosmeceuticals LLC (Obagi medical)
15.3.8.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2 Product Portfolio
15.3.8.3 SWOT Analysis
15.3.8.4 Strategic Overview
15.3.9 Vivier Pharma
15.3.9.1 Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2 Product Portfolio
15.3.9.3 SWOT Analysis
15.3.9.4 Strategic Overview

List of Tables

Table 01: Global Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 02: Global Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 03: Global Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 04: Global Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Region, 2016–2026
Table 05: North America Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Country, 2016–2026
Table 06: North America Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 07: North America Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 08: North America Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 09: Europe Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 10: Europe Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 11: Europe Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 12: Europe Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 13: Asia Pacific Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 14: Asia Pacific Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 15: Asia Pacific Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 16: Asia Pacific Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 17: Latin America Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 18: Latin America Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment Type, 2016–2026
Table 19: Latin America Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 20: Latin America Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 21: Middle East & Africa Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 22: Middle East & Africa Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Treatment, 2016–2026
Table 23: Middle East & Africa Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 24: Middle East & Africa Hyperpigmentation Disorders Treatment Market Size (US$ Mn) Forecast, by End-user, 2016–2026
Table 25: Bayer AG Business Overview
Table 26: Allergan Business Overview
Table 27: Galderma S.A. Business Overview
Table 28: SkinCeuticals Business Overview
Table 29: Pierre Fabre Business Overview
Table 30: EpiPharm AG Business Overview
Table 31: RXi Pharmaceuticals Corporation Business Overview
Table 32: Obagi Cosmeceuticals LLC Business Overview
Table 33: Vivier Pharma Business Overview